Supernus Pharma (SUPN) Reports Q4 Revenue of $155M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 4:06 PM ESTPreliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early October 2022Completed acquisition of Adamas Pharmaceuticals, Inc. in November 2021; integration well underwayQelbree® continued its growth trajectory, closing the year with 13,380 prescriptions in December 2021
ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the... More
